GlaxoSmithKline allegedly tried to intimidate Avandia critic
Pharma Compliance Alert, November 21, 2007
GlaxoSmithKline (GSK) allegedly tried to silence Dr. John Buse, an independent scientist who criticized GSK's diabetes drug Avandia, according to a Senate Finance Committee report.
At scientific meetings in 1999, Buse gave speeches suggesting Avandia carried cardiovascular risks. In July 2007, FDA scientists estimated Avandia had caused approximately 83,000 excess heart attacks since coming on the market.
According to the report, GSK branded Buse a "renegade" and silenced his concerns about Avandia by complaining to his superiors and threatening a lawsuit.
Click here to read the Senate Finance Committee's press release.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- HIPAA Q&A: Level of encryption needed for email
- OB services: Coding inside and outside of the package
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- What does case-mix index mean to you?
- ED-to-inpatient transfers are flawed with safety gaps
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Searched